To explore the potential benefits of Ruthenibacterium lactatiformans and ILA on fat metabolism and obesity (which were highly elevated by about 19.71-fold and 2.04-fold during CF) and the strong correlation with fat metabolic indicators, mice were fed an HFD or co-administrated Ruthenibacterium lactatiformans or ILA alternately every other day for 9 weeks. The gene discussed is TNFRSF9; the disease is cystic fibrosis.